RxDoctor Payments Data

Giant Lin, MD

Otolaryngology · Florham Park, NJNPI 1699933044

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $17,700 of the $24,947 with a category attached, or 71.0%. Optinose US, Inc. accounts for 79.2% of it on its own, with 16 other manufacturers making up the rest. 2025 is the largest year on record at $13,946, more than ten times the $420 reported in 2019. Among otolaryngology clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$24,947in general payments, 2019–2025

Across 87 payments — averaging $286.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Optinose US, Inc.$20K
  • Medical Device Business Services, Inc.$1K
  • Intersect ENT, Inc.$736
  • Aerin Medical Inc.$632
  • Medtronic$482
  • Integra Lifesciences Corporation$477
  • plus $2K from 11 others

What the payments were for

  • Speaking & faculty fees$17,70071%
  • Travel & lodging$1,7967%
  • Food & beverage$5,45122%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,947 in reported general payments places this provider in the 95th percentile of 232 otolaryngology providers in New Jersey.

See all otolaryngology providers in New Jersey

Medicare billing

Part B allowed, 2024
$534,628
Medicare patients
531
Services billed
2,736

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XhanceFluticasone Propionate22$19,383
Budesonide19$3,576
Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth28$2,923
Fluticasone Propionate110$2,308
Ipratropium Bromide54$2,266
Prednisolone Acetate23$1,381
Azelastine Hcl41$1,242
Famotidine54$1,127
Omeprazole38$975
Pantoprazole Sodium70$958
Rabeprazole Sodium16$831
Fluocinolone Acetonide Oil19$684
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav59$620
Cefdinir29$505
Mupirocin39$431

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Optinose US, Inc.Xhance$19,767$19,38322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 232 otolaryngology providers in New Jersey.

Other otolaryngology in Florham Park

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →